Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and GM-CSF in Multi-metastatic NSCLC
NCT02940990Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sargramostim in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
sargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02940990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940990.